Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Anticancer Research

• Publication date

  1995-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 8572622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Steroid receptor enhancement by natural interferon-beta in advanced breast cancer.

  1993cited by this paper
• Heterogeneity of the alpha-interferon-mediated overexpression of class-I and class-II major histocompatibility complex molecules in primary cultured cancer cells.

  1993cited by this paper
• Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer.

  1992cited by this paper
• Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

  1991cited by this paper
• Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells.

  1990cited by this paper
• Sensitivity and insensitivity of breast cancer to tamoxifen.

  1990cited by this paper
• Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

  1987cited by this paper
• Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen.

  1987cited by this paper
• Effect of natural beta‐interferon on cell proliferation and steroid receptor level in human breast cancer cells

  1987cited by this paper
• A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

  1984cited by this paper
• Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.

  1983cited by this paper
• Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.

  1982cited by this paper
• Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors.

  1982cited by this paper
• Tamoxifen‐induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: A case report and review of the literature

  1981cited by this paper
• Changes in multiple or sequential estrogen receptor determinations in breast cancer

  1980cited by this paper
• Assessment of response to therapy in advanced breast cancer.

  1977cited by this paper

• Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives

  2022cites this paper
• Interferons: role in cancer therapy.

  2020cites this paper
• Optimizing mouse models for precision cancer prevention

  2016cites this paper
• Cytokines in the management of high risk or advanced breast cancer: an update and expectation.

  2009cites this paper
• Immune manipulation of advanced breast cancer: An interpretative model of the relationship between immune system and tumor cell biology

  2009cites this paper
• ImmuneManipulation ofAdvancedBreast Cancer : An InterpretativeModel of the Relationship Between Immune System andTumor Cell Biology

  2008cites this paper
• Cytokines in breast cancer.

  2006cites this paper
• Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.

  2005influential citation
• A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients

  2002cites this paper
• Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).

  2002cites this paper
• Interferons in the therapy of solid tumors. Part III. Interferon and various solid malignancies

  2000cites this paper
• Interferon-beta: Structure, differential actions, and medical applications

  1997cites this paper